FDA maintains clinical hold on DiaMedica's ReMEDy2 stroke trial; cash $36.1M

DiaMedica Therapeutics Inc.

FDA requires additional in-use IV stability study (tubing + pump) to lift clinical hold on Phase 2/3 ReMEDy2 trial.
Cash, equivalents, and marketable securities were $36.1M as of Sept 30, 2022; Q3 cash burn $2.3M.
Company will request Type A FDA meeting to confirm study design and gain guidance toward resumption.
Three transient hypotension cases led to hold; all patients recovered without lasting effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.